---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-012199"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:04:58.697992+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics reports Q4 net loss $24.6M, cash $362M; key trial data due 1Q24

## Summary
- Net loss Q4 $24.6M ($0.25/sh) vs $19.6M ($0.26) YoY; full year loss $85.9M.
- Cash & equivalents $362.1M vs $155.5M year-end 2022, funding pipeline milestones.
- Phase 2 VENTURE (VK2735, obesity) topline results expected in 1Q24; oral VK2735 Phase 1 data also 1Q24.
- Phase 2b VOYAGE (VK2809, NASH) 52-week histology results expected in 1H24.
- Phase 1b VK0214 for X-ALD results expected in 1H24.

## SEC filing metadata
- accession: 0000950170-24-012199
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024012199/0000950170-24-012199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024012199/vktx-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-012199
- JSON: https://secwatch.observer/filing/0000950170-24-012199.json
- Plain text: https://secwatch.observer/filing/0000950170-24-012199.txt

## Key facts
- Earnings Releases
  Viking Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on its clinical pipeline and other corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017024012199/0000950170-24-012199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.